The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*
Open accessAbstract
BACKGROUND: Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin-13, a key driver of atopic dermatitis (AD). OBJECTIVES: To evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids (TCS) in patients with moderate-to-severe AD who were candidates for systemic therapy. METHODS: This was a double-blind, placebo plus TCS controlled phase III trial. Patients were randomized 2 : 1 to subcutaneous tralokinumab 300 mg or placebo every 2 weeks (Q2W) with TCS as needed over 16 weeks. Patients who achieved an Investigator's Global Assessment (IGA) score of 0/1 and/or 75% improvement in Eczema Area and Severity Index (EASI 75) at week 16 with tralokinumab were rerandomized 1 : 1 to tralokinumab Q2W or every 4 weeks (Q4W), with TCS as needed, for another 16 weeks. RESULTS: At week 16, more patients treated with tralokinumab than with placebo achieved IGA 0/1: 38·9% vs. 26·2% [difference (95% confidence interval): 12·4% (2·9-21·9); P = 0·015] and EASI 75: 56·0% vs. 35·7% [20·2% (9·8-30·6); P < 0·001]. Of the patients who were tralokinumab responders at week 16, 89·6% and 92·5% of those treated with tralokinumab Q2W and 77·6% and 90·8% treated with tralokinumab Q4W maintained an IGA 0/1 and EASI 75 response at week 32, respectively. Among patients who did not achieve IGA 0/1 and EASI 75 with tralokinumab Q2W at 16 weeks, 30·5% and 55·8% achieved these endpoints, respectively, at week 32. The overall incidence of adverse events was similar across treatment groups. CONCLUSIONS: Tralokinumab 300 mg in combination with TCS as needed was effective and well tolerated in patients with moderate-to-severe AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic features of atopic dermatitis
Hanifin, J. M., & Rajka, G. (1980) · Acta Dermato-Venereologica · doi:10.2340/00015555924447 · Cited by 5,086
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,596
Atopic Dermatitis: Global Epidemiology and Risk Factors
Nutten, S. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000370220 · Cited by 3,055
Weidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908
Self-citationWeidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Self-citationGuidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Self-citationWollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14888 · Cited by 684
Self-citationWollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J. ‐., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19574 · Cited by 638
Self-citationTsoi, L. C., Rodriguez, E., Degenhardt, F., Baurecht, H., Wehkamp, U., Volks, N., Szymczak, S., Swindell, W. R., Sarkar, M. K., Raja, K., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.12.018 · Cited by 469
Self-citationTreatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Wollenberg, A., Howell, M. D., Guttman-Yassky, E., Silverberg, J. I., Kell, C., Ranade, K., Moate, R., & van der Merwe, R. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.05.029 · Cited by 409
Self-citationInterleukin‐13: Targeting an underestimated cytokine in atopic dermatitis
Bieber, T. (2020) · Allergy · doi:10.1111/all.13954 · Cited by 382
Self-citationSimpson, E. L., Bruin-Weller, M., Flohr, C., Ardern-Jones, M. R., Barbarot, S., Deleuran, M., Bieber, T., Vestergaard, C., Brown, S. J., Cork, M. J., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.06.042 · Cited by 241
Self-citationTsoi, L. C., Rodriguez, E., Stölzl, D., Wehkamp, U., Sun, J., Gerdes, S., Sarkar, M. K., Hübenthal, M., Zeng, C., Uppala, R., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.11.047 · Cited by 216
Self-citationPopovic, B., Breed, J., Rees, D. G., Gardener, M. J., Vinall, L. M. K., Kemp, B., Spooner, J., Keen, J., Minter, R., Uddin, F., et al. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.12.005 · Cited by 198
Boguniewicz, M., Alexis, A. F., Beck, L. A., Block, J., Eichenfield, L. F., Fonacier, L., Guttman-Yassky, E., Paller, A. S., Pariser, D., Silverberg, J. I., et al. (2017) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2017.08.005 · Cited by 191
Self-citationRelative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis
Tazawa, T., Sugiura, H., Sugiura, Y., & Uehara, M. (2004) · Archives of Dermatological Research · doi:10.1007/s00403-004-0455-6 · Cited by 132
Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin
Szegedi, K., Lutter, R., Res, P., Bos, J. D., Luiten, R. M., Kežić, S., & Middelkamp-Hup, M. A. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13160 · Cited by 118
May, R. D., Monk, P., Cohen, E. S., Manuel, D. V. F. P., Dempsey, F. C., Davis, N. H. E., Dodd, A., Corkill, D. J., Woods, J. M., Joberty-Candotti, C., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01659.x · Cited by 107
Wang, C., Kraus, C. N., Patel, K. G., Ganesan, A. K., & Grando, S. A. (2020) · International Journal of Dermatology · doi:10.1111/ijd.14573 · Cited by 78
Abraham, S., Haufe, E., Harder, I., Heratizadeh, A., Kleinheinz, A., Wollenberg, A., Weisshaar, E., Augustin, M., Wiemers, F., Zink, A., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18958 · Cited by 53
Self-citationWeidinger, S., Tollenaere, M. A. X., Drerup, K. A., Litman, T., & Norsgaard, H. (2019) · SKIN The Journal of Cutaneous Medicine · doi:10.25251/skin.3.supp.42 · Cited by 2
Self-citation
Cited by
Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J. ‐., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19574 · Cited by 638
Self-citationEuropean guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
Wollenberg, A., Kinberger, M., Arents, B., Aszodi, N., Avila Valle, G., Barbarot, S., Bieber, T., Brough, H. A., Calzavara Pinton, P., Christen‐Zäch, S., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18345 · Cited by 426
Self-citationReich, K., Teixeira, H. D., de Bruin-Weller, M., Bieber, T., Soong, W., Kabashima, K., Werfel, T., Zeng, J., Huang, X., Hu, X., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00589-4 · Cited by 402
Self-citationKaplon, H., & Reichert, J. M. (2021) · mAbs · doi:10.1080/19420862.2020.1860476 · Cited by 292
Davis, D. M. R., Drucker, A. M., Alikhan, A., Bercovitch, L., Cohen, D. E., Darr, J. M., Eichenfield, L. F., Frazer-Green, L., Paller, A. S., Schwarzenberger, K., et al. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.08.102 · Cited by 265
Self-citation
Metadata
- Authors
- Silverberg, J. I., Toth, D., Bieber, T., Alexis, A. F., Elewski, B. E., Pink, A. E., Hijnen, D., Jensen, T. N., Bang, B., Olsen, C. K., Kurbasic, A., Weidinger, S., & the ECZTRA 3 study investigators
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-02-22
- Volume
- 184
- Issue
- 3
- Pages
- 450-463
- ISSN
- 0007-0963 (ISSN-L)
- 1365-2133
- OpenAlex
- W3090227268
- Cited by
- 326
- References
- 22
- FWCI
- 26.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.